Literature DB >> 11250868

HMG-CoA reductase inhibitors and P-glycoprotein modulation.

K Bogman1, A K Peyer, M Török, E Küsters, J Drewe.   

Abstract

1. Five 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), (e.g. atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin), were investigated for their ability to reverse P-glycoprotein (P-gp) mediated rhodamine 123 (R123) transport in a murine monocytic leukaemia cell line that over-expresses the multi-drug resistance protein 1a/b (mdr1a/1b). 2. P-gp modulation was studied by a fluorimetric assay and confocal microscopy by means of R123 efflux and uptake experiments, respectively. 3. Atorvastatin acid, methyl ester and lactone, lovastatin lactone and simvastatin lactone inhibited R123 transport in a concentration-dependent manner. Lovastatin acid, simvastatin acid, fluvastatin and pravastatin did not show a significant inhibition of the R123 transport in our cell system. Atorvastatin methyl ester and lactone showed the highest affinities for P-gp and results were comparable for both methods. 4. In conclusion, monitoring of R123 transport in living cells by confocal microscopy in addition to fluorimetric assay is a sensitive tool to study P-gp affinity in drug screening that is especially useful for early phases of drug development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250868      PMCID: PMC1572659          DOI: 10.1038/sj.bjp.0703920

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Drug Interactions: A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management.

Authors: 
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

3.  Indirect coupling of organic anion secretion to sodium in teleost (Paralichthys lethostigma) renal tubules.

Authors:  D S Miller; J B Pritchard
Journal:  Am J Physiol       Date:  1991-12

4.  The interaction of diltiazem with simvastatin.

Authors:  O Mousa; D C Brater; K J Sunblad; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2000-03       Impact factor: 6.875

Review 5.  'Fire and forget?' - pharmacological considerations in coronary care.

Authors:  M Bottorff
Journal:  Atherosclerosis       Date:  1999-09-09       Impact factor: 5.162

6.  Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.

Authors:  H C Maltz; D L Balog; J S Cheigh
Journal:  Ann Pharmacother       Date:  1999-11       Impact factor: 3.154

7.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.

Authors:  B Hsiang; Y Zhu; Z Wang; Y Wu; V Sasseville; W P Yang; T G Kirchgessner
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

8.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.

Authors:  B A Masters; M J Palmoski; O P Flint; R E Gregg; D Wang-Iverson; S K Durham
Journal:  Toxicol Appl Pharmacol       Date:  1995-03       Impact factor: 4.219

Review 9.  Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview.

Authors:  G Ecker; P Chiba
Journal:  Wien Klin Wochenschr       Date:  1995       Impact factor: 1.704

10.  Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

Authors:  R A Halpin; E H Ulm; A E Till; P H Kari; K P Vyas; D B Hunninghake; D E Duggan
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

View more
  48 in total

1.  Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Authors:  Jasper Dingemanse; Dieter Schaarschmidt; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

3.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

4.  Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives.

Authors:  Tomasz Grzela; Agata Bialoszewska; Robert Brawura-Biskupski-Samaha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

Review 5.  Safety and efficacy of statins in Asians.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2006-12-15       Impact factor: 2.778

Review 6.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

7.  Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.

Authors:  Matthew W Davis; Suman Wason
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

8.  Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.

Authors:  Anjana Munshi
Journal:  Hum Genet       Date:  2012-07-19       Impact factor: 4.132

9.  Statin-associated polymyositis following omeprazole treatment.

Authors:  Rajan Kanth; Milind S Shah; Rafael Medina Flores
Journal:  Clin Med Res       Date:  2013-04-11

10.  Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.

Authors:  Anna Martirosyan; James W Clendening; Carolyn A Goard; Linda Z Penn
Journal:  BMC Cancer       Date:  2010-03-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.